Loading…
← CockpitCompetitor Analysis › 4114.TWO Synmosa Biopharma CorpOpen in the cockpit ↗

Synmosa Biopharma Corp4114.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major
Momentum neutral 59
Mkt cap
$423M
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$717,749
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-0.1 pp
WACC 5.0%
Hurdle
-10 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · TWDNT$26.30
1D-0.9%
1W-5.2%
1M-13.2%
3M-11.7%
6M-1.3%
YTD-6.7%
1Y-9.2%
ATR %2.0%
52w lowhigh16.2% off high

What Synmosa Biopharma does

Employees: 586

Synmosa Biopharma at a glance

Size Synmosa Biopharma (4114.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $423M, the 488th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$26.30 on 18 Nov 2026.

Performance Over six months the shares fell 1.3%, against -26.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 21.0% over the last twelve months (peer median +3.4%); the operating margin is 10.2% (peer median -10.6%).

Valuation It trades at 2.2× enterprise value to sales against a peer median of 3.3× (7th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.1 points below its cost of capital (5.0% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 20264114.TWO 99Peer median 77
Six months, rebased to 100: Synmosa Biopharma against the median of its 20 peers (local-currency closes).

Synmosa Biopharma financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$7.39BNT$6.19BNT$5.55BNT$5.14BNT$4.39B
Revenue growth—+12%+8%+17%—
Gross profitNT$2.72BNT$2.54BNT$2.25BNT$1.97BNT$1.69B
EBITDANT$1.12BNT$1.12BNT$1.08BNT$956MNT$780M
Net incomeNT$832MNT$822MNT$685MNT$595MNT$799M
Free cash flowNT$196MNT$134MNT$535MNT$262MNT$449M
Capital expenditureNT$340MNT$281MNT$270MNT$270MNT$184M
Total debtNT$4.19BNT$2.52BNT$2.55BNT$2.44BNT$3.37B

Quarterly statements and history in the cockpit →

Synmosa Biopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%601089001060TVGN048410603139002728OVIDZOTA600613002923PHAT6881176050776881367871RZLTCTMX0005180007880029004114.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. Synmosa Biopharma is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%+6,000%0×100×200×601089001060048410OVID78710005184114.TWORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Synmosa Biopharma is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%0010600027286006130029236881170007884114.TWOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Synmosa Biopharma is the large dot.

Synmosa Biopharma competitors and peer comparison

How Synmosa Biopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Synmosa Biopharma against its 20 peers (data as of 18 Nov 2026)
Measure4114.TWOPeer medianRank in peer set
1-month return-13.2%-11.8%10th lowest of 21
6-month return-1.3%-26.3%5th highest of 21
Distance from 52-week high-16.2%-51.3%highest of 21
Revenue growth (TTM)+21.0%+3.4%7th highest of 19
Operating margin10.2%-10.6%3rd highest of 19
EV / Sales2.2×3.3×7th cheapest of 19
Growth the price implies (Req g, 7 yrs)5.4%0.6%3rd most demanding of 7
Growth delivered (Del g)+15.3%+4.3%highest of 7
Hurdle (Req g minus delivered)-9.8 pp+1.3 pp3rd least demanding of 7
ROIC minus cost of capital-0.1 pp-8.2 pp7th highest of 18
EV / EBITDA14.5×n/a—
Net debt / EBITDA1.1×n/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Synmosa Biopharma 4114.TWOTaiwan$423M-1%+21%10%2.2×5.4%+15.3%
Beijing Foyou Pharma 601089.SSChina$423M-27%+5%10%0.2×n/an/a
JW Pharmaceutical 001060.KSSouth Korea$423M-26%+9%13%0.7×-15.4%+7.2%
Tevogen TVGNUnited States$422M-38%n/an/an/an/an/a
Hyundai Bioscience 048410.KSSouth Korea$424M-50%+78%-580%164.0×n/an/a
Shaanxi Kanghui Pharmaceutical Co 603139.SSChina$421M-31%+1%-39%7.1×n/an/a
Teyi Pharmaceutical 002728.SZChina$419M-12%-7%7%3.2×24.4%+8.0%
Ovid Therapeutics OVIDUnited States$427M-5%-78%-4,700%208.3×n/an/a
Zota Health Care ZOTA.NSIndia$427M+9%+69%-16%6.2×n/an/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SSChina$427M+4%-4%3%1.2×10.6%+1.4%
Zhuhai Rundu Pharmaceutical 002923.SZChina$430M-30%+14%5%2.2×1.4%-1.3%
Phathom Pharmaceuticals PHATUnited States$431M-55%+87%-9%2.9×n/an/a
Cheng Du Sheng Nuo Biotec 688117.SSChina$433M-48%+51%27%3.4×-0.2%+14.5%
Zhejiang Huakang Pharmaceutical 605077.SSChina$433M-47%+35%4%1.1×n/an/a
Kexing Biopharm 688136.SSChina$433M-42%-14%-12%2.9×n/an/a
Elixiron Immunotherapeutics (Cayman) 7871.TWOTaiwan$412M+64%+6,162%-194%119.7×n/an/a
Rezolute RZLTUnited States$411M+32%n/an/an/an/an/a
CytomX Therapeutics CTMXUnited States$410M-49%-88%-676%4.7×n/an/a
Jiangsu Sihuan Bioengineering 000518.SZChina$437M-8%-17%-28%10.6×n/an/a
PKU Healthcare 000788.SZChina$437M-12%-49%5%2.1×-5.6%-5.6%
Harbin Medisan Pharmaceutical 002900.SZChina$437M-16%-5%-29%4.2×n/an/a

Questions

Which companies are Synmosa Biopharma's closest peers?
The cockpit's peer set: Beijing Foyou Pharma (601089.SS), JW Pharmaceutical (001060.KS), Tevogen (TVGN), Hyundai Bioscience (048410.KS), Shaanxi Kanghui Pharmaceutical Co (603139.SS), Teyi Pharmaceutical (002728.SZ), Ovid Therapeutics (OVID), Zota Health Care (ZOTA.NS).
Is Synmosa Biopharma expensive compared with its peers?
On ev / sales it trades at 2.2× against a peer median of 3.3×, 7th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Synmosa Biopharma stock performed?
Over six months to 18 Nov 2026 the shares returned -1.3% against -26.3% for the median peer; over one year -9.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.